Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)

Inclusion Criteria: * Female participants aged ≥18 years and ≤60 years at the time of signing the informed consent form. * Presentation of female pattern hair loss in stages 2 to 4 of the Sinclair scale (Women's Alopecia Severity Scale - WASS), based on the Investigator's clinical examination. * Absence of specific treatment for female pattern hair loss (FPHL) in the last 6 months or history of specific treatment for FPHL lasting ≤30 days in the last 6 months. Participants currently using specific treatment for FPHL or with prior use lasting \>30 days in the last 6 months must complete a 3-month washout period before the Randomization Visit (RV). * Willing to agree to all procedures and assessments required by the clinical trial, including a permanent tattoo applied to the scalp and shaving of the target area. * Willing to maintain hair style, length, and color throughout the study. * Willing to maintain consistent use of hair care products and general hair care routine during the entire study. Exclusion Criteria: * Participant presenting other causes of alopecia, such as: alopecia areata, scarring alopecia, traction alopecia, nutritional deficiency, monilethrix, trichotillomania, trichothiodystrophy, chemotherapy-induced alopecia. * Participant who experienced telogen effluvium in the last 6 months, such as after childbirth, infection, intense stress. * Participant presenting other dermatological conditions on the scalp, such as: seborrheic dermatitis, psoriasis, eczema, …